PURE Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2022
March 15, 2022 at 04:11 pm EDT
Share
PURE Bioscience, Inc. reported earnings results for the second quarter and six months ended January 31, 2022. For the second quarter, the company reported revenue was USD 0.416 million compared to USD 0.916 million a year ago. Net loss was USD 0.702 million compared to USD 0.595 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
For the six months, revenue was USD 0.917 million compared to USD 2.51 million a year ago. Net loss was USD 1.5 million compared to USD 0.775 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago.
PURE Bioscience, Inc. is focused on developing and commercializing its proprietary antimicrobial products primarily in the food safety arena. The Company provides solutions to combat the health and environmental problems of pathogen and hygienic control. Its technology platform is based on patented, stabilized ionic silver, and its initial products contain silver dihydrogen citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds. The Company offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. It also offers PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The Company sells its products directly and indirectly through third-party distributors.
PURE BIOSCIENCE, INC. 
